Dataset from A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005, PT008, and Open-label Symbicort® Turbuhaler®, as an Active Control, on Lung Function Over a 24-Week Treatment Period in Subjects With Moderate to Very Severe COPD

This is a Phase III randomized, double-blind, parallel group, multi-center, 24-week lung function study with BFF MDI (320/9.6 μg and 160/9.6 μg) compared to FF MDI 9.6 μg, BD MDI 320 μg, and open-label Symbicort® TBH (200/6 μg) administered BID.

本研究为一项III期随机双盲平行组多中心肺功能研究，周期为24周，旨在对比BFF MDI（320/9.6 μg与160/9.6 μg）、FF MDI 9.6 μg、BD MDI 320 μg以及开放标签制剂Symbicort® TBH（200/6 μg）的临床效果，所有受试药物均采用每日两次（BID）给药方案。